Researchers aim to overcome resistance to bowel cancer screening in Scots

Academics are to look at ways to encourage Scots to take part in a new national screening programme for bowel cancer, a leading cause of cancer deaths in Western nations.

The research team, led by the University of Edinburgh, wants to overcome resistance to the scheme from some higher risk Scots, as early screening for the disease has already proved effective in reducing death rates from bowel cancer.

The researchers will focus their efforts on encouraging low uptake groups which include men, those who live in areas of deprivation and people who belong to certain ethnic groups, to be screened for early-stage bowel cancer. In Scotland, there is no significant difference in incidence of the disease across socio-economic groups but survival rates are poorer amongst lower income groups.

Professor David Weller, Head of General Practice at the University of Edinburgh and leader of the study, said: "With the announcement of a new screening programme for bowel cancer in Scotland, it is particularly important to reach groups of people who would benefit from it most. One such group in Scotland includes those on low incomes, who tend to have higher rates of most illnesses related to lifestyle factors such as smoking, diet and physical inactivity, and who would benefit from this new cancer screening programme.

"Screening has been seen to cut death rates in the population, and we have evidence to show that a national screening programme would be successful. However, we still don't know how well our strategies using primary care to target low-uptake groups are working. This study will fill in an important gap in our knowledge."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Neoantigen DNA vaccines improve survival and immunity in triple-negative breast cancer patients